soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The Study Oral Semaglutide Reduces Cardiovascular Events

"This is a hundred percent central thing

* Additional details on other secondary outcomes other than the change in body weight can be found at as NCT03954834 (SURPASS-1), NCT03987919 (SURPASS-2), NCT03882970 (SURPASS-3), NCT03730662 (SURPASS-4), NCT04039503 (SURPASS-5), NCT04537923 (SURPASS-6), NCT04255433 (SURPASS-CVOT), NCT03861052(SURPASS J-mono), NCT04093752 (SURPASS-AP-Combo), and NCT04184622 (SURMOUNT-1)

GLP-1s and related drugs can lead to health benefits beyond weight loss

What to Expect During Medical Consultations Your healthcare provider will likely perform a thorough examination and ask you several questions to understand your condition better